NUCALA 100 mg, solution for injection in a pre-filled pen 3 pens of 1 ml
Active ingredients: MÉPOLIZUMAB
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection3 pens of 1 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NUCALA 100 mg, solution injectable en stylo prérempli
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 3 stylos préremplis en verre de 1 mL
- Marketing authorisation holder
- GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 24 Jan 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63236206CIP73025056CIP133400930250563Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉPOLIZUMABsolution | 100 mg · un stylo prérempli de 1 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.